ARTICLE | Targets & Mechanisms
GeNeuro goes retro
How GeNeuro is exploring beyond MS for new indications for its HERV platform
June 11, 2015 7:00 AM UTC
GeNeuro S.A. put human endogenous retroviruses on the map as drug targets for multiple sclerosis, but new data point to a pathological role for the viruses in a much broader spectrum of diseases. Now GeNeuro is looking to academia to help explore ways of expanding the pipeline beyond its primary MS-targeted asset - once the company's platform is proven in the clinic.
Last month, GeNeuro gathered its academic collaborators and other leading researchers on human endogenous retroviruses (HERVs) at the HERVs & Disease meeting in Lyon, France, to discuss the role of HERV family members in diseases ranging from amyotrophic lateral sclerosis (ALS) to cancer...